Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Summit Therapeutics Says Ivonescimab Plus Chemotherapy Cuts Death Risk 25% in Phase III Biliary Tract Cancer Trial

By Public Technologies
  • Summit Therapeutics announced ivonescimab with chemotherapy improved overall survival versus durvalumab with chemotherapy in first-line advanced biliary tract cancer.
  • Results from partner Akeso’s China-based Phase III HARMONi-GI1 trial are being presented today at the ESMO 2026 Congress in Madrid.
  • The regimen also delayed disease progression, with a manageable safety profile and no additional safety signals.
  • A US registration-enabling Phase II/III trial with ECOG-ACRIN is expected to begin site activation in the fourth quarter of 2026.
  • Ivonescimab remains investigational in the United States and Europe.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610251152BIZWIRE_USPR_____20261025_BW603151) on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.